Virtual Clinical Trials: A complete Remote concept

Virtual Industry revenues will reach to $7.2 billion globally by the end of 2017 as in Greenlight Insight’s latest report. Anticipating modest growth in the short term, expects the Virtual industry to grow into a major global marketplace by 2021, reaching $74.8 billion in global revenues. Virtual industry remarkably uses cases including Tourism, Education, Sales and Marketing, designing and sports coaching.

How about on Clinical Trial Industry?

Clinical Trial industry is facing crisis, nearly 80% of trials do not meet enrollment timelines, and these delays can amount to $8 million in lost revenues per day, according to one estimate by Cutting edge information. But now the industry is preparing to bet on new trend: Virtual Clinical Trials. Virtual Clinical Trials represent a relatively new method of collecting safety and efficacy data from clinical trial participants. Imaging few scenario on this.

  • Patients do not travel to sites.
  • Devices (it can be mobile, watch, glass) link to the clinical research study and reporting general information including Adverse Events.
  • Device’s sensors record data like body temperature, blood glucose levels and which are sent automatically to EDC record.
  • Study personnel visits at patient’s home for drug administration and follow up.
  • Whenever visits are approaching, mobile device provide automated reminders and allowing them to reschedule according to protocol.
  • And this is just beginning of what the future is likely to hold for virtual clinical trials.
  • Evolve in Virtual Clinical Trial (VCT):
    1. Pfizer evolved the VCT model with its Research on Electronic Monitoring of Overactive bladder Treatment Experience (REMOTE) trial in 2011. It was the first randomized clinical trial using web and smartphone based recruitment, enrollment and collection of study data without requiring patients to visit a site.

    Experiences: It was halted in 2012 because of poor recruitment. Patient recruitment (most members of the target patient group were older), so the use of technology based trial was an unknown.

    2. Sanofi announced its intention to support a virtual diabetes trail (VERKKO) to be conducted remotely in Europe in 2015. Instead of testing drug, Pfizer’s trial did, Sanofi’s tested a wireless glucose meter in diabetes patients. Also it is the first clinical trial using an electronic ICF approved by European regulatory agencies.

    Experiences: 97% retention rate and are completed at least 30% faster than a traditional trial.

  • Although totally remote research is still a relatively new concept and still has limitations. VCT can be inappropriate for phase I and other acute problems like strokes which are probably a bad idea to monitor at home.

    FDA is seeking on specific issues like how the FDA could encourage adoption of such tools, how new models of research will affect patients. FDA has established docket to gather feedback on how researchers are using technology and what are the barriers which are stopping.

    Forthcoming of VCT:

    • Patients who were previously excluded can now participate, for example patients living in rural areas would finally have a chance to enroll without travelling to a central center.
    • Pfizer case study and FDA docket suggest multitude of challenges to come in the journey to make VCT a viable choice for study sponsors.
    • Need to think differently on patient privacy and protection.
    • Recruitment and retention of patients with low computer literacy is a major concern that can greatly impact the trial and data it generates. These are the scenario which seems convincing.
    • Perhaps VCT can be used in rescue studies where traditional models have failed. Example: for geographically dispersed groups or rare disease populations.
    • It will not be an easy road, but it is one likely to offer significant benefits for certain studies and select populations.
    • Biggest roadblock to VCT adoption is the industry itself, which is highly regulated and slow to adopt new things.
    • With supportive technologies and the right Virtual trial model, VCT is sure to become more popular in Pharma and medical device developers in near future.

    If you make the trial easy, satisfying and rewarding for patients, they will want to take part. What is your opinion on VCT model?AAEAAQAAAAAAAA2IAAAAJDgxYzI4MmQ4LTNkZjktNDJlOS05MzE5LTczMTFkMWFjYzRmZg.png

Advertisements

Risk Based Monitoring- Opportunity or Obstacles

Risk Based Monitoring- Opportunity or Obstacles

“Analyst have been manually examined thousands of data points in clinical research but with the vast and ever increasing amount of data available, the human brain is unable to do it all.”

Data are coming from operational and laboratory which requires technology to bring these together into something meaningful and actionable. What are these technology which enables to work more efficiently on actual performance?

Applicable steps for Risk Based Monitoring

Let’s break the process into steps,

  • Determine risk at both protocol and site level
  • Define performance brink
  • Determine key risk indicators
  • Determine action and response plans
  • Define communication plans
  • Ensure continuous review and reassessment
  • Adjust the plan when necessary
  • Provide midterm performance indicators showing how site compare, enabling action or escalation of action as needed
  • Trend long term site performance, showing what to monitor, and how much to monitor, whether performed on site or remotely

Risk based monitoring has gained considerable scrutiny in recent years hesitation still remains around the approach. In some cases, risk based strategy could replace the need for such frequent site visits to quarterly or even once a year instead of industry standard of every four to six weeks. A risk based approach with good judgment and sound reasoning can greatly curtail the need for CRAs to be road warriors.

 big_157062

What are the things that any mid-size CRO can appliance for RBM?

  1. Develop monitoring plan appropriate for the trial
  2. Conduct early dispute with team members to clearly define
  • How to assess risks
  • Outline statistical analysis
  • Identify what monitors review
  1. Develop robust risk management plan at the beginning of the study
  2. Potential risks and strategies to mitigate them should be reviewed regularly with sponsor/CRO partners throughout the life of trial to optimize efficiency decision making and in taking action when risks become reality.
  3. Establish solid communication pathways for issue discussion and escalation with key team members.
  4. Pull together different values and presptives from various team members and start with the end in mind.
  5. Be actively involved in identifying triggers, trending and modeling and programming for data as it is ongoing.
  6. Frequent ongoing communication with PM, DM CRAs and Biostatician.
  7. Focus less on source verification and more on source data review and analysis.
  8. Support clinical sites in developing their own internal quality management plans.

Obstacles for slower adoption

  • Commercial Interestrsz_changesahead
  • People concerns
  • Technology hurdles

 

 

Commercial Interest

Wait for others to move which is first common strategy, effort to reduce risk as you can learn from others mistakes. And most of the CROs are dependent on monitoring visits to generate their revenue, and scared that they will have to face long term losses until it’s established. Let me tell you in very simple language why anyone wants to change wheels while it is already moving?

People concerns

This is something related to industry people, as they are well experienced and have to face process change. Everyone has to be part of change, writing metrics too and most importantly “Expertise” tag. “Expertise” tag is going to change in “learning new model”.

Technology Hurdles

Powerful challenge among all, development of whole new system needs strong IT team which is lacking in every Indian CRO or hire third party developer to establish data integrated system. Clinical trial data are to be regularly reviewed for outliers, errors, or other non-compliances, and large volumes of data need to be processed, and it would be require the use of validated and well-designed computerized to minimize the workload.

Conclusion

Risk-Based Monitoring (RBM) is changing the way companies are conducting clinical trials. Adopting RBM requires changes to a company’s processes and tools for monitoring. Risk Based Monitoring is one solution to combat the continually rising costs of conducting effective clinical trials.  Shifting the costs away from onsite visits and 100 0ercent source data verification toward centralized data collection and monitoring, limited sources and budgets can be better utilized to ensure data quality.

Implementing technology will be critical in strategies to increase efficiency and deliver accurate analyses of clinical study site performance and data quality. However the challenges of moving toward an alternative monitoring approach have slowed industry-wide implementation, the future looks bright for Risk Based Monitoring. The word “risk” is going to reduce risk with “Risk Based Monitoring”.